ARDT Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 3.51%, SMA50 5.97%, SMA200 -19.68%). The stock’s 14-day RSI is 55.41 (neutral), while the ATR of 0.34 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -39.19% below its high and over 17.47% above its low. Average 10-day trading volume of 302.18 thousand shares is below the 3-month average of 360.17 thousand, indicating normal recent market interest.

Ardent Health Partners, LLC last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $22.46. This means the shares are trading below this model’s fair value.

Ardent Health Partners, LLC has 142.90 million shares outstanding. The public float is 24.25 million shares, elevated short interest at 8.40% of float. This equals 2.78 million shares. The short ratio is 6.34 days. Institutional investors hold 97.71% of the float. Insiders own 23.11%.

Ardent Health Partners, LLC (NYSE:ARDT) closed at $8.66 USD, losing -$0.01 (-0.12%) from the previous close of $8.67. The stock is currently mid-range between its 52-week high and low $8.07 and $15.48. With a market capitalization of about $1.24 billion, Ardent Health Partners, LLC is classified as a small-cap and shows lower-than-market volatility (beta ~0.45). Key stats such as the average daily volume over the past year has been around 401.69 thousand shares, volume is running light vs its 52-week average. Headquartered in Brentwood, TN, Ardent Health Partners, LLC operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Martin J. Bonick, the company employs approximately 19,200 people and listed since July 18, 2024. Ardent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States.

Wall Street analysts project EPS growth of -2.16% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 5 Buy ratings, 5 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $20.00 to $10.00. The high target offers 130.95% upside. The low target suggests 15.47% downside. The mean target is $15.30. This offers 76.67% upside. Ardent Health Partners, LLC earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by 22.64%. The prior quarter beat by 73.33%. Over the last six quarters, Apple has recorded several small beats. These include 16.67% in August 14, 2024.

Our AI price prediction model suggests that Ardent Health Partners, LLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.12%, with price expected at $8.13 by April 16, 2026, within a range of $7.89 to $8.39 3-Month Outlook: Projected fall of -31.76%, reaching $5.91 by July 01, 2026, with a range of $5.13 to $6.46. 1-Year Outlook: Projected loss of -38.45%, with price at $5.33 by April 02, 2027, within a range of $4.86 to $5.78.

Ardent Health Partners, LLC (NYSE:ARDT) shares are flat -6.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Ardent Health Partners, LLC trading at a premium to the broader market with a P/E of 8.98. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $17.85, suggesting 106.12% upside. Our AI forecast model points to short-term weakness (-6.12% over two weeks), a medium-term fall (-31.76% over three months), and a longer-term loss (-38.45% over one year), with expected trading ranges indicating moderate volatility.

Ardent Health Partners, LLC trades at a P/E ratio of 8.98, slightly below the S&P 500 average, with a price-to-sales ratio of 0.2 and a price-to-book ratio of 0.72 suggesting the stock is closer to book value. The P/FCF stands at 4.87, also above market averages.